Abstract: The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products induced by IL-13.
Type:
Application
Filed:
December 1, 2009
Publication date:
January 5, 2012
Applicant:
Cincinnati Children's Hospital Medical Center
Abstract: Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increase a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention further relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia, a lysosomal storage disease. The invention further relates to a method of improving and/or correcting one or more central nervous system (CNS) abnormalities caused by one or more lysosomal storage disease.
Type:
Application
Filed:
December 6, 2010
Publication date:
December 1, 2011
Applicant:
Cincinnati Children's Hospital Medical Center
Inventors:
Johannes Christiaan Maria Van Der Loo, Dao Pan, Punam Malik
Abstract: Gene expression in peripheral blood from individuals with Duchenne muscular dystrophy (DMD), compared to control individuals, demonstrated differential gene sets that could be used in a method to diagnose DMD, to evaluate effect of DMD therapy, and/or to evaluate propensity to DMD.
Type:
Application
Filed:
October 14, 2009
Publication date:
April 29, 2010
Applicants:
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, THE UNIVERSITY OF CALIFORNIA AT DAVIS
Inventors:
Brenda L. Wong, Frank R. Sharp, Lisa Lit
Abstract: The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.
Type:
Grant
Filed:
November 18, 2005
Date of Patent:
November 3, 2009
Assignee:
Cincinnati Children's Hospital Medical Center
Inventors:
Yi Zheng, Huzoor Akbar, David A. Williams, Wieslaw Adam Mazur